Baxter Bros Inc. Has $365,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Baxter Bros Inc. boosted its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.3% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 896 shares of the pharmaceutical company’s stock after buying an additional 76 shares during the period. Baxter Bros Inc.’s holdings in Vertex Pharmaceuticals were worth $365,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of VRTX. abrdn plc boosted its position in shares of Vertex Pharmaceuticals by 196.0% during the 4th quarter. abrdn plc now owns 581,018 shares of the pharmaceutical company’s stock valued at $236,410,000 after purchasing an additional 384,730 shares in the last quarter. BSN CAPITAL PARTNERS Ltd bought a new position in shares of Vertex Pharmaceuticals during the 4th quarter worth approximately $81,378,000. Jennison Associates LLC grew its position in shares of Vertex Pharmaceuticals by 3.9% during the 4th quarter. Jennison Associates LLC now owns 3,944,913 shares of the pharmaceutical company’s stock worth $1,605,146,000 after buying an additional 147,248 shares during the period. Northern Trust Corp increased its stake in shares of Vertex Pharmaceuticals by 4.9% in the 3rd quarter. Northern Trust Corp now owns 2,813,563 shares of the pharmaceutical company’s stock valued at $978,388,000 after acquiring an additional 131,539 shares in the last quarter. Finally, International Assets Investment Management LLC lifted its position in shares of Vertex Pharmaceuticals by 21,750.1% during the 4th quarter. International Assets Investment Management LLC now owns 115,150 shares of the pharmaceutical company’s stock valued at $46,853,000 after acquiring an additional 114,623 shares during the period. Institutional investors own 90.96% of the company’s stock.

Vertex Pharmaceuticals Stock Performance

Vertex Pharmaceuticals stock traded up $0.92 during mid-day trading on Friday, reaching $401.08. 1,064,066 shares of the company’s stock were exchanged, compared to its average volume of 1,004,237. The business’s fifty day simple moving average is $409.06 and its 200 day simple moving average is $399.73. The company has a quick ratio of 3.78, a current ratio of 3.99 and a debt-to-equity ratio of 0.02. Vertex Pharmaceuticals Incorporated has a one year low of $320.01 and a one year high of $448.40. The firm has a market capitalization of $103.66 billion, a PE ratio of 28.88, a P/E/G ratio of 1.89 and a beta of 0.39.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, topping analysts’ consensus estimates of $3.85 by $0.35. The company had revenue of $2.52 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Vertex Pharmaceuticals had a return on equity of 21.91% and a net margin of 36.68%. During the same period in the previous year, the business posted $3.33 EPS. On average, sell-side analysts expect that Vertex Pharmaceuticals Incorporated will post 14.95 earnings per share for the current year.

Analyst Ratings Changes

VRTX has been the topic of several research reports. Robert W. Baird lowered shares of Vertex Pharmaceuticals from a “neutral” rating to an “underperform” rating and set a $325.00 price objective on the stock. in a report on Wednesday, January 31st. Guggenheim increased their price target on Vertex Pharmaceuticals from $445.00 to $450.00 and gave the stock a “buy” rating in a report on Thursday, April 18th. William Blair restated an “outperform” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, February 6th. HC Wainwright lifted their price target on shares of Vertex Pharmaceuticals from $457.00 to $462.00 and gave the company a “buy” rating in a research report on Thursday, April 11th. Finally, Wolfe Research began coverage on shares of Vertex Pharmaceuticals in a research note on Thursday, February 15th. They set an “outperform” rating and a $515.00 price target for the company. Three research analysts have rated the stock with a sell rating, six have assigned a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $430.86.

Insiders Place Their Bets

In other news, EVP Ourania Tatsis sold 354 shares of the stock in a transaction that occurred on Monday, February 26th. The shares were sold at an average price of $425.70, for a total transaction of $150,697.80. Following the completion of the transaction, the executive vice president now directly owns 55,804 shares of the company’s stock, valued at approximately $23,755,762.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Ourania Tatsis sold 354 shares of the company’s stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $425.70, for a total value of $150,697.80. Following the transaction, the executive vice president now owns 55,804 shares in the company, valued at $23,755,762.80. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Jeffrey M. Leiden sold 2,656 shares of the firm’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $419.51, for a total value of $1,114,218.56. Following the completion of the sale, the chairman now directly owns 27,644 shares of the company’s stock, valued at $11,596,934.44. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 12,381 shares of company stock valued at $5,203,249. Company insiders own 0.20% of the company’s stock.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.